Ayurvedic drug promises cure for vitiligo

Vitiligo or Leucoderma is a skin condition that is usually not medically harmful, and is non-contagious, but, causes white spots or patches to appear on skin.

Vitiligo affects a person’s appearance, and the social stigma attached to it, usually leaves a psychological scar on those suffering from the condition. Although various kinds of medicines and treatments across all streams of medicine have been advised to the patients with this condition across the globe, these have not helped cure the condition. Moreover, they are either costly or single component based, with low level of efficacy.

Finally an Ayurvedic drug developed by the DRDO Scientists has claimed a cure to Vitiligo. The drug, by name ‘Lukoskin’, was initially developed in 2012, after several comprehensive research and clinical trials by the scientists of Defence Bio-Energy Research Centre (DIBER) in India (Haldwani, Uttarakhand).

Comprising an ointment and an oral liquid, the patients consume the drug over a period of 300 to 400 days for effective results. AIMIL Pharmaceuticals in Delhi have been given the authority to manufacture the drug.
The drug was presented at the International Arogya Festival 2017 in Delhi, organized by the Ministry of Ayush in India.

A senior DRDO scientist, Hemand Pande, mentioned that while allopathic medicines mask the disease, the condition usually resurfaces when the patient stops taking medicine. In this, case it is not to be so.
Now, ‘Lukoskin’ is beginning to gain attention from pharmaceutical companies across the globe.

With increasing number of people switching to ayurvedic medicines, the government plans to make the drug accessible to not just Indian markets, but to global market as well.

According to dermatologists, Vitiligo is caused due to lack of melanin, the pigment that gives skin its color. The body’s immune system attacks the pigment cells, mistaking them for foreign invaders.

Worldwide, the incidence of Vitiligo is about 1 to 2 percent, but, in India it is about 4 to 5 percent. Lack of awareness, myths, and stigma attached to Leucoderma are perhaps the most pressing challenges that take a toll on the social and psychological health of patients.

Keeping in view increasing acceptance for alternate traditional medicines and ensured accountability, various government bodies are undertaking research in ancient old formulations and transferring technology to the commercial firms for public benefits.